STEM-21. CLINICAL RELEVANCE OF CANCER STEM CELL CYTOTOXICITY ASSAY IN GUIDING TREATMENT FOR GLIOBLASTOMA

BACKGROUND. The prognosis of glioblastoma (GBM) treated with standard-of-care regimens remains very poor with a median time to recurrence of 7-9 months, and a median survival of 15-18 months. GBMs contain a small, but resilient population of cancer stem cells (CSCs) that contribute to tumor initiati...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Pier Paolo, Claudio, Ranjan, Tulika, Howard, Candace, Yu, Alexander, Xu, Linda, Aziz, Khaled, Jho, David, Leonardo, Jodi, Denning, Krista, Valluri, Jagan
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Cancer Stem Cells
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651437/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.838
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares